Nano Dimension (NNDM) Issues Update on Infinite Epigenetics Combination
Nano Dimension (NASDAQ:NNDM) and Infinite Epigenetics issued a June 16 shareholder update on their proposed business combination announced June 15. Nano said final terms are still being negotiated after reviewing a recent letter, and it described Infinite’s operations and lab capabilities. The company said the deal values NNDM at net cash plus a 20% premium and is subject to shareholder approval.
How this was made
The 30-second read
Why it matters
For NNDM, the key tradable takeaway is deal progression without final terms. The company’s framing of Infinite as an operating, revenue-generating CLIA lab may support the strategic narrative, but the absence of finalized transaction specifics limits immediate valuation clarity.
Market read
This is a deal-status update that can influence deal probability and expectations, but it does not disclose definitive terms or a signed agreement.
What to watch
Traders may be underweighting the conditional nature of the transaction, including the shareholder vote requirement and the lack of definitive agreement terms in this update.
Background
Nano Dimension and Infinite Epigenetics announced a proposed business combination in mid-June 2026 and issued a shareholder update on June 16, responding to a recent letter and reiterating that details are still being negotiated.
Ticker impact
Nano Dimension updates shareholders on its proposed combination with Infinite Epigenetics, saying final terms are still being negotiated and will be disclosed later.
Near-term trading likely remains headline-driven, with limited directional conviction until definitive deal terms and shareholder-vote details are released.
The article provides a shareholder update rather than a finalized agreement, emphasizing ongoing negotiations and conditionality on a future shareholder vote.
Market effects
Highlights continued interest in AI-enabled diagnostics and epigenetics platforms, but provides no new sector-wide regulatory or funding datapoints.
No specific regional market impact beyond Nano’s global manufacturing footprint.
No direct global macro or cross-border transaction details beyond the described combination.
Counterpoint
The update may reduce upside conviction because it stresses that final transaction details are still being negotiated, implying deal risk remains.
Key entities
- public_companyNano Dimension Ltd.
NASDAQ-listed company issuing the shareholder update on the proposed combination with Infinite Epigenetics.
- public_or_private_companyInfinite Epigenetics
Counterparty in the proposed business combination, described as an operating business with CLIA-certified lab and commercial revenue.
